Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Impact and Outcomes of Combined Cerebrolysin and Amantadine Sulfate Administration on Management of Patients With Traumatic Brain Injury in the ICU

NCT06052787 is registered in ClinicalTrials.gov with Ain Shams University as lead sponsor.

NCT NCT06052787
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06052787 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Impact and Outcomes of Combined Cerebrolysin and Amantadine Sulfate Administration on Management of Patients With Traumatic Brain Injury in the ICU
Lead sponsor
Ain Shams University
Phase
Phase 3
Overall status
Completed
Start date
September 1, 2023
Completion date
August 1, 2025
Enrollment
150 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

traumatic brain injury